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Aims To explore variations in invasive care of the elderly with acute coronary syndromes across inter-
national practice.
Methods and results Using combined populations from the SYMPHONY and 2nd SYMPHONY trials, we
describe 30-day cardiac catheterization in elderly (75 years; n ¼ 1794) vs. younger patients (,75
years; n ¼ 14 043) after multivariable adjustment and by region of enrolment. The use of cardiac cathe-
terization and revascularization were not protocol-speciﬁed. Elderly patients (median age 78 years)
were more often female and more frequently had hypertension, diabetes, prior myocardial infarction,
and prior coronary bypass surgery. Overall, they underwent less cardiac catheterization than younger
patients [53 vs. 63%; adjusted OR 0.53 (0.46, 0.60)]. The absolute rate of cardiac catheterization in
the elderly varied from 77% (vs. 91% in younger patients) in the US cohort to 27% (vs. 41% in younger
patients) in the non-US cohort. Revascularization of elderly who underwent cardiac catheterization
was also higher in US than non-US cohorts (71.3 vs. 53.6%). There was a signiﬁcant interaction
between the patient age and the use of catheterization across US and non-US regions of enrolment,
as well as differences in the predictors of catheterization in the elderly. Despite these ﬁndings, after
adjustment, 90-day rates of death and death or myocardial infarction (MI) were not signiﬁcantly
different in elderly who underwent catheterization compared with those who did not.
Conclusion Although older age is universally predictive of lower use of cardiac catheterization, marked
variation in catheterization of the elderly exists across international practice. Demonstrated differences







In the setting of uncertainty regarding risk and beneﬁt,
invasive care in elderly cardiac patients may be subject
to cultural differences in health care values, practice pat-
terns, or resources. Such international differences in health
care culture, practice, and economics have been well
described.1–3 These forces may be particularly inﬂuential
when decision-making is complex and the evidence is
limited. The use of cardiac catheterization in the elderly
with acute coronary syndromes (ACS) is such an area
where limited evidence and patient complexity allow for
practice to evolve in disparate ways. Furthermore, the
decision to proceed with cardiac catheterization in
elderly ACS patients is a simultaneous reﬂection of their
eligibility for revascularization if signiﬁcant blockages are
found. Thus, the rates of invasive care reﬂect assessments
of eligibility for both catheterization and revascularization.
The decision for invasive care also encompasses consider-
ations of resources, patient preferences, and provider
judgments. In the US, elderly patients with ACS undergo
less invasive care relative to younger patients despite its
important role in risk stratiﬁcation following NSTE ACS.4
The largest remaining gap in ACS care between the old
and young is in the use of an invasive strategy. To our
knowledge, there has not been another comparison of
the inﬂuence of patient age on the use of invasive care
across international practice. Therefore, we determined
if invasive care in the elderly is similarly low or varies in
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important ways across international practice. Our primary
goal was to describe patterns of invasive care as a function
of age, and to identify predictors of catheterization in the
elderly. Using the databases from two large international
clinical trials, Sibraﬁban vs. aspirin to Yield Maximum
Protection from ischaemic Heart events post-acute cOroN-
ary sYndromes trials (SYMPHONY) and 2nd SYMPHONY, we
compared the use of cardiac catheterization and sub-
sequent revascularization in elderly patients 30 days fol-
lowing their ACS in US and non-US regions.
Methods
Patient population
The SYMPHONY trials enrolled patients with ACS from August 1997 to
August 1999 in 931 clinical centers in 37 countries across ﬁve
continents. The methods and results of the SYMPHONY and 2nd
SYMPHONY trials have been previously published.5–7 Brieﬂy, SYMPH-
ONY randomized 9233 patients with ACS to aspirin or sibraﬁban in
one of the two doses (high or low) without concomitant aspirin.5,6
The 2nd SYMPHONY trial randomized 6671 patients to high-dose
sibraﬁban, low-dose sibraﬁban plus aspirin, or aspirin.7 Enrolment
criteria were the same for both trials and included chest pain or
anginal-equivalent symptoms lasting for 20 min and either positive
cardiac markers or electrocardiographic changes consistent with
ischaemia. Patients enrolled in these studies had their qualifying
ACS event (ST-segment elevation or non-ST-segment elevation MI
or unstable angina) within 7 days prior to enrolment and were clini-
cally stable for 12 h. Exclusion criteria for both trials included
serious illness, major surgery, predisposition to bleeding, prior
stroke or intracranial haemorrhage, and serum creatinine
.1.5 mg/dL. The primary endpoint in SYMPHONY was the 90-day
composite of death, (re)MI, or severe recurrent ischaemia leading
to unplanned revascularization. The time to this composite was
the primary endpoint in 2nd SYMPHONY, in which the median treat-
ment duration was 90 (35, 138) days. The SYMPHONY and 2nd
SYMPHONY trials were approved by local Ethics Committees and
institutional review boards and all patients gave written informed
consent to participate.
Study design
The current study is a retrospective observational analysis from the
combined databases of the two SYMPHONY trials. After excluding 67
patients without a recorded age, the ﬁnal analysis population was
15 837 subjects. All outcomes were compared across the age
groups, with elderly deﬁned as age 75 years. The primary
outcome of interest was the use of cardiac catheterization 30
days from the initial presentation with an ACS. Secondary analyses
included referral for percutaneous coronary intervention (PCI) or
coronary bypass surgery (CABG) among those undergoing cardiac
catheterization. Death and death or MI at 90 days are shown
unadjusted and adjusted for variables in the previously published
SYMPHONY models,8 which include the region of enrolment.
Regional comparisons
The 37 countries participating in SYMPHONY and 2nd SYMPHONY
were grouped into seven regions (Table 1).3 Because of the estab-
lished differences in treatment patterns between the US and
Canada, and the much larger enrolment in the US, Canada was
included with the non-US practice.9
Statistical analysis
Baseline characteristics and use of procedures are shown overall for
age ,75 and 75 years, and again for age 75 years among the US
and the non-US practices. Descriptive statistics summarizing base-
line demographic and clinical characteristics are presented as per-
centages for discrete variables, and medians (25th and 75th
percentiles) for continuous variables. In addition, death for age
,75 and 75 years, and for elderly undergoing catheterization in
comparison with those not undergoing catheterization are
described.
Using multivariable logistic regression, a model was created from
the entire population identifying baseline characteristics associated
with the use of cardiac catheterization within 30 days (catheteriza-
tion adjustment model). A second model was developed exclusively
in the elderly population (age 75) to predict the use of cardiac
catheterization among patients older than 75 years. An unbiased
approach to variable selection was used such that all characteristics
available from the case report form were considered initially and
reﬁned using clinical input from the investigators.
Variables considered in the modelling for factors associated with
the use of catheterization included region, baseline demographic
and clinical characteristics (age, race, sex, weight, height, body
mass index), past medical history and risk factors (prior PCI, CABG
or cardiac catheterization; prior MI, angina, heart failure; diabetes,
hypertension, hypercholesterolaemia, smoking status, family
history of coronary artery disease, atrial ﬁbrillation, and cancer),
qualifying ACS event details [type of qualifying event (QE) (MI or
unstable angina), electrocardiographic changes (left bundle
Table 1 Enrolment by region
Region Countries in region Regional enrolment
(n, % of trial total)
Regional elderly
enrolment
(n, % age  75 of
region total)
North America United States 7165 (45.2) 920 (12.8)
Canada 867 (5.5) 106 (12.2)
Australia/New Zealand Australia, New Zealand 647 (4) 73 (11.3)
Western Europe Austria, Belgium, Denmark, Finland, France,
Germany, Greece, Iceland, Ireland, Israel,
Italy, The Netherlands, Norway, Portugal,
South Africa, Spain, Sweden, Switzerland,
United Kingdom
3409 (22) 392 (11.5)
Latin America Argentina, Brazil, Chile, Mexico 557 (4) 54 (9.7)
Eastern Europe Bulgaria, Czech Republic, Hungary,
Poland, Romania
2647 (17) 202 (7.6)
Asia China, Hong Kong, Singapore, Taiwan, Thailand 545 (4) 47 (8.6)
International variation in invasive care 1559
branch block, pseudonormalization, ST-segment depression, T-wave
inversion, ST-segment elevation), cardiac marker status, heart rate,
blood pressure, serum creatinine, creatinine clearance, Killip class,
mitral regurgitation, pulmonary oedema], and clinical details and
events occurring from the QE to enrolment [time to treatment
from QE and occurrence of atrioventricular block, ventricular ﬁbril-
lation, recurrent ischaemia, and congestive heart failure (CHF)].
Signiﬁcant variables (P, 0.05) were retained and interaction
terms between region and key variables as well as a variable for
non-US enrolment were tested. The linearity of continuous variables
in the models was tested using restricted cubic splines. Signiﬁcant
variables in the overall catheterization model included age,
weight, race, angina in prior 6 weeks, CHF, prior PCI, prior angina,
smoking, insulin use, and QE variables of HR, CHF, Q-waves on
EKG, and recurrent ischaemia. Signiﬁcant variables in the elderly
catheterization model are shown in Table 2.
The adjusted association of cardiac catheterization with 90-day
mortality in the elderly was determined using the previously devel-
oped 90-day SYMPHONY mortality model, adjusting also for the pro-
pensity score for use of catheterization as a continuous variable in
the outcome model. Because cardiac catheterization was a post-
randomization factor in an observational analysis, we display
results, but caution against over-interpretation of these adjusted
analyses. The 90-day mortality modelling methods and the ﬁnal
model have been previously published;8 the ﬁnal mortality model
included age, QE CHF, randomization heart rate, prior CHF,
pre-randomization PCI, ACE-inhibitor use, creatinine clearance,
prior TIA, streptokinase use, QE MI, prior MI, Latin America,
control arm, prior chronic obstructive pulmonary disease, angina
within prior 6 weeks, hypertension, and prior angiography.
All statistical analyses were performed using SAS version 8.2
statistical software (SAS Institute, Cary, NC, USA).
Results
Patient population
Among the 15 837 patients in our analysis, more than half
(n ¼ 8672) were enrolled in the six non-US regions (55%
non-US vs. 45% US). The majority of non-US patients were
enrolled in Western Europe (22%), followed by Eastern
Europe (17%), Canada (5%), and 4% each from Latin
America, Australia, New Zealand, and Asia (Table 1).
Overall, 11.3% (n ¼ 1794) of the enrolled population were
elderly (75 years old). The proportion of the elderly
varied slightly by region, and was highest in the US,
Canada, and Western Europe (range: 8–13%) (Table 1).
Compared with patients ,75 years, elderly patients were
more often female, with lower body weight and creatinine
clearance, and had more hypertension, diabetes, prior
cardiac diagnoses than younger patients. They were less
likely to be current smokers (Table 3). The elderly presented
with higher Killip class, more CHF, and QE, which were more
often unstable angina (vs. MI in younger patients).
Baseline characteristics in the elderly population (age
75 years) varied slightly by region (Table 3). The non-US
elderly were younger (77 vs. 78 years), weighed less (71
vs. 73 kg), and had less diabetes (19.8 vs. 21.7%) and hyper-
tension (51.4 vs. 63.8%) than the US elderly. Conversely,
they had higher rates of current smoking (11 vs. 8%) and
angina in the prior 6 weeks (48.4 vs. 40.4%). The US
elderly more often had a history of cardiac procedures
prior to enrolment than the non-US elderly.
Predictors of cardiac catheterization in
the elderly
Variables that were associated with the use of invasive care
among the elderly (age 75) are shown in Table 2. Among
patients 75 years, each year of advancing age was associ-
ated with a 15% lower likelihood of cardiac catheterization
[OR per 1 year ¼ 0.85 (0.82, 0.88)]. Elderly patients were
less likely to undergo cardiac catheterization if they had
QE Killip class .1, or heart rate .60 bpm, and were more
likely to undergo catheterization if they had angina in the
previous six weeks. In the non-US regions, prior MI was
associated with a lower likelihood of catheterization,
whereas prior CHF or prior PCI was associated with a
greater likelihood. The relationships were opposite within
US care, with prior CHF associated with a lower, and prior
MI and prior PCI tending to a higher likelihood of catheteri-
zation. Enrolment in all non-US regions was associated with
a lower likelihood of invasive care in the elderly in
comparison with enrolment in the US.
Cardiac catheterization by region and age
The highest rate of cardiac catheterization in the elderly
occurred in the US (77 vs. 27% non-US). The non-US cathe-
terization rates ranged from a high of 53% in Asia to a low
of 5% in Eastern Europe. The rate of cardiac catheterization
among patients ,75 years was 91% in the US compared with
41% in the non-US practice (Table 4). Rates of cardiac cathe-
terization among younger patients were higher than among
the elderly in all regions, but the relative differences in
use by age group varied by region.
After accounting for factors that are associated with the
undergoing cardiac catheterization, elderly patients (age
75) were half as likely as younger patients to undergo
cardiac catheterization [OR 0.53 (0.46, 0.60)] (Table 4). In
general, this pattern held across all regions, with the excep-
tion of Asia where no age difference in the use of cardiac
catheterization was observed after adjustment [OR 1.19
(0.58, 2.09)]. The difference in use by age was greatest in
Table 2 Multivariable predictors of cardiac catheterization at
30 days post-ACS in the elderly
Variable OR
US enrolmenta 8.35 (5.09, 13.69)
Eastern Europea 0.08 (0.04, 0.16)
Age per 1 yearb 0.85 (0.82, 0.88)
QE Killip . 1 0.60 (0.43, 0.83)
Prior CHF (non-US enrolment) 1.48 (0.77, 2.86)
Prior CHF (US enrolment) 0.37 (0.23, 0.59)
Prior PCI (non-US enrolment) 4.68 (2.27, 9.64)
Prior PCI (US enrolment) 1.22 (0.75, 1.97)
QE MI (non-US enrolment) 0.58 (0.40, 0.83)
QE MI (US enrolment) 1.06 (0.70, 1.58)
Angina within 6 weeks prior to QE 1.30 (1.00, 1.67)
QE heart rate 60 bpm 1.04 (0.99, 1.09)
QE heart rate .60 bpm 0.99 (0.98, 0.99)
Weight 55 kg 1.15 (1.07, 1.24)
Weight .55 kg 1.00 (0.99, 1.01)
Control arm 1.43 (1.10, 1.85)
aReference group for US and Eastern Europe is Western Europe, Canada,
Australia/New Zealand, Latin America, and Asia.
bAge per 1 year with signiﬁcant age by region interaction (Figure 1),
heart rate per 1 bpm increase, weight per 1 kg increase.
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Eastern Europe [OR 0.33 (0.17, 0.63)]. The continuous
relationship between advancing age and the use of cathe-
terization varied signiﬁcantly across the US and non-US
regions as displayed in Figure 1. A decline in catheterization
in both US and non-US regions was observed as age
increased, and was most noted after 75 years of age.
However, there was a signiﬁcant age-by-region interaction
(US region *age, P ¼ 0.006). This was due to the higher
rate of catheterization in younger patients in US practice
that was followed by a rapid decline in older patients
compared with the more gradual decline with age in
non-US practice.
Of note, the majority of cardiac catheterizations per-
formed within the ﬁrst 30 days were performed within the
ﬁrst 2 days following QE (55%). Early catheterization was
more common in the US practice than in the non-US practice
(70 vs. 27%). In addition, early catheterization was more
common among younger patients than older patients in the
US (71 vs. 59%), but not in the non-US practice (27 vs. 25%).
Table 3 Baseline characteristics by age and region of enrolment
Overall (age,75,
n ¼ 14 043)
Overall (age  75,
n ¼ 1794)
United States
(age  75, n ¼ 920)
Non-United States
(age  75, n ¼ 874)
Demographics and history
Age (years)a 58 (50, 65) 78 (76, 81) 78 (76, 82) 77 (76, 80)
Weight (kg)a 82 (72, 93) 72 (63, 81) 73 (64, 82) 71 (63, 80)
Female 25.0 (3492) 47.0 (843) 49.0 (449) 45.0 (394)
Non-white 13.0 (1847) 9.7 (173) 9.0 (87) 10.0 (86)
Current smoker 41.0 (5694) 9.0 (169) 8.0 (73) 11.0 (96)
Past smoker 32.0 (4424) 39.0 (699) 44.0 (402) 34.0 (297)
History of CHF 3.6 (510) 9.8 (175) 11.9 (109) 7.6 (66)
Hypertension 48.5 (6803) 57.8 (1035) 63.8 (586) 51.4 (449)
Diabetes 17.8 (2496) 20.8 (373) 21.7 (200) 19.8 (173)
Angina in prior 6 weeks 43.9 (6158) 44.5 (798) 40.8 (375) 48.4 (423)
Prior MI 19.3 (2707) 26.8 (480) 28.4 (261) 25.1 (219)
Prior PCI 10.7 (1502) 11.3 (203) 17.4 (159) 5.0 (44)
Prior coronary bypass surgery 8.5 (1174) 13.4 (236) 20.4 (186) 5.8 (50)
Prior atrial ﬁbrillation 3.1 (437) 9.4 (169) 10.5 (97) 8.2 (72)
Creatinine clearance (mL/min/1.73 m2)a 91 (73, 113) 55 (45, 66) 56 (46, 68) 53 (45, 64)
QE details
QE MI 73.6 (10376) 69.3 (1250) 73.9 (679) 65.4 (571)
ST elevation on QE electrocardiogram 55.5 (7700) 44.2 (782) 38.5 (349) 50.1 (433)
QE heart rate (per 5 bpm)a 76 (65, 88) 75 (65, 88) 76 (65, 88) 75 (65, 88)
QE systolic blood pressure (mmHg)a 140 (123, 160) 145 (129, 167) 146 (128, 167) 145 (130, 165)
Elevated cardiac markers at QE 82.7 (11 321) 80.3 (1405) 84.3 (756) 76.2 (649)
QE Killip class  II 10.0 (1382) 17.5 (310) 15.9 (145) 19.1 (165)
Recurrent ischaemia from QE to enrolment 7.7 (1087) 8.1 (145) 7.3 (67) 9.0 (78)
All values are percentages and (frequencies).
aMedians (25th, 75th percentiles).
Table 4 Cardiac catheterization 30 days post-ACS in elderly
compared with younger patients
Region Age ,75%






Overall 63 (8814) 53 (944) 0.53 (0.46, 0.60)
US 91 (5658) 77 (705) 0.40 (0.33, 0.50)
Non-US 41 (3156) 27 (239) 0.61 (0.52, 0.73)
Asia 56 (279) 53 (25) 1.10 (0.58, 2.09)
Latin America 53 (268) 41 (22) 0.53 (0.28, 1.03)
Western Europe 54 (1620) 33 (131) 0.44 (0.34, 0.56)
Canada 42 (318) 29 (31) 0.50 (0.30, 0.84)
Australia/
New Zealand
51 (292) 26 (73) 0.34 (0.19, 0.63)
Eastern Europe 16 (379) 5 (11) 0.33 (0.17, 0.63)
Shown as % (n). Figure 1 Log OR plot of likelihood of undergoing diagnostic cardiac
catheterization during 30 days post-ACS as a function of patient age adjusted
for all factors predictive of the use of catheterization. Three lines represent
the overall, US, and non-US relationship between catheterization and age.
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Diagnostic testing and revascularization
Cardiac catheterization was the most commonly used diag-
nostic test in all regions (Table 5). The invasive approach
in the US practice extended to the use of revascularization
among elderly who undergo catheterization (71% of elderly
patient undergoing cardiac catheterization being revascu-
larized in the US vs. 54% in the non-US cohort). Use of
alternative risk stratiﬁcation with stress testing and echo-
cardiography was low across all regions, but more common
in the non-US cohort (19.7% US vs. 37.6% non-US).
Considering the combined use of invasive or non-invasive
testing (excluding echo), the number of elderly tested in
Canada, Australia/New Zealand, and Western Europe
increased, but there was little increment in testing observed
in regions with either high or low rates of invasive care (US,
Asia, and Eastern Europe). For example, Eastern Europe had
the lowest use of any cardiac testing (10%) and the lowest
use of stress testing (5%) (Table 5). Overall, 69% of the
elderly patients in SYMPHONY underwent some form of
cardiac risk assessment (81% US vs. 56% non-US), and
about a third of elderly who had a catheterization went on
to some form of revascularization (Table 5).
Outcomes in the elderly
Elderly patients had worse 90-days outcomes compared with
younger patients even after adjusting for baseline differ-
ences, region of enrolment, and use of invasive care. Death
at 90 days was 1.4% for age ,75 and 5.3% for age 75
[adjusted OR 1.8 (1.3, 2.5)]. Among the elderly (age 75
years), those who underwent catheterization had lower
rates of death overall (4.2 vs. 6.5% no catheterization), and
in US (3.7 vs. 6.5% no catheterization), and non-US (5.9 vs.
6.5% no catheterization) practices. However, the trends to
higher mortality among those not undergoing catheterization
were no longer signiﬁcant after adjustment for predictors of
mortality and propensity for cardiac catheterization in the
overall population [adjusted OR 1.18 (0.67, 2.07)], or in the
US [adjusted OR 1.42 (0.60, 3.38)] or in the non-US regions
[adjusted OR 1.11 (0.50, 2.45)].
Discussion
Variations in international practice have indeed been
previously described,1,2,9–11 but have now also been
demonstrated to extend to invasive management of the
elderly. We found that although the absolute rate of
cardiac catheterization in the elderly is markedly higher in
a US cohort, regardless of the region, the use of catheteriza-
tion declined with age. The relative use of catheterization in
elderly vs. younger patients varied by region and local care
patterns. In regions where invasive care was uncommon, like
Eastern Europe, we observed the greatest additional decre-
ment with age. However, even in the US cohort in which the
absolute rate was highest, the relative reductions in cathe-
terization past the age of 75 were notable and demonstrate
a signiﬁcant interaction between the age and the procedure
used. Thus, while invasive care is more directly inﬂuenced
by age in high resource use areas like the US, factors like
availability and resources may be more inﬂuential in
non-US regions. Interestingly, in our analysis, Asia was the
only region where age was not associated with the use of
cardiac catheterization, though this ﬁnding was from data
in only 47 patients.
Lower availability of catheterization labs and longer
waiting times for procedures have been demonstrated in
Canada where the wait time between MI and angioplasty
was 28 days compared with less than 2 days in the US.1
These forces are similar in other health care systems as
well. Although the invasive care over the last decade has
increased in Canada and the US, the US practice remains
more invasive in comparison after accounting for differences
in wait times, physician speciality, and procedure avail-
ability.12 In health care environments where catheterization
is less available, management may focus on risk-
stratiﬁcation testing. However, we found that differences
in invasive management were not explained by alternative
risk stratiﬁcation testing between the US and the non-US
practices. Although these care patterns raise questions
regarding the inﬂuence of culture and resources on patient
management, one can only speculate regarding their long-
term impact.
Comparable or lower rates of death have been reported
among post-MI patients in the US compared with non-US
regions.13 In addition, a better quality of life in the year
following an MI has also been demonstrated in regions with
high rates of invasive management.10,14 The randomized
use of invasive care had recently been evaluated in a large
meta-analysis, which demonstrated lower rates of MI,
angina, and rehospitalization when early catheterization
Table 5 Regional use of cardiac testing and revascularization at 30 days post-ACS in the elderly








All patients (1794) 14 (247) 19 (349) 53 (944) 69 (1234) 67 (631) [54, 14]
US (920) 11 (101) 11 (103) 77 (705) 81 (747) 71 (503) [58, 13]
Non-US (874) 17 (146) 28 (246) 27 (239) 56 (487) 54 (128) [39, 15]
Asia (47) 2 (1) 17 (8) 53 (25) 62 (29) 44 (11) [40, 4]
Latin America (54) 7 (4) 19 (10) 41 (22) 52 (28) 45 (10) [18, 27]
Western Europe (392) 23 (90) 25 (96) 33 (131) 57 (225) 58 (76) [44, 15]
Canada (106) 22 (23) 22 (23) 29 (31) 58 (61) 58 (18) [48, 13]
Australia/New Zealand (73) 23 (17) 23 (17) 26 (19) 62 (45) 47 (9) [26, 21]
Eastern Europe (202) 5 (11) 46 (92) 5 (11) 49 (99) 36 (4) [18,18]
aEither coronary angiography or echocardiography or stress testing. Shown as % (n).
bPCI or coronary bypass surgery among population who underwent coronary angiography. Shown as % (n) [%PCI, %CABG].
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was an assigned treatment.15 However, beneﬁts from inva-
sive care clearly vary based on the population studied, use
of revascularization and concomitant therapies, and the
duration of follow-up. For example, patients who are
managed with a selective invasive approach have also
been shown to have similar outcomes at 1 year in a random-
ized trial.16 In all these trials, few ‘very elderly’ were
included, and similarly only 12% of the SYMPHONY popu-
lation was over 75.17 However, beneﬁts of an invasive strat-
egy for ACS among elderly (age .70) has recently been
demonstrated in the TACTICS-TIMI 18 trial, which showed
fewer rehospitalizations and less death and MI during short-
term follow-up.18–21 Over time, elderly with chronic angina
also achieve beneﬁts from invasive management over
optimal medical treatment, with fewer adverse cardiac
events and rehospitalizations at 1 year.22 Our data conﬁrm
that the elderly are at high risk, but found no differences
in outcomes for elderly patients as a function of invasive
management after adjusting for predictors of catheteriza-
tion and mortality.
We were not able to assess the impact of invasive manage-
ment on quality of life or symptom status. However, given
that selected high-risk elderly do well with an invasive
approach, and knowing that recurrent ischaemic events
are common, age should not exclude patients from invasive
evaluation.23 The use of invasive care in selected high-risk
patients regardless of age is supported by European and
American guidelines for unstable angina and non-ST-segment
elevation MI.24,25 Despite their potential for beneﬁt, the
elderly remain less likely to undergo cardiac catheterization
across international practice, with a particular decline
related to age seen within the highly invasive US practice.
Many unresolved issues remain in the care of elderly
patients with coronary artery disease. Our data demonstrate
that the elderly who are selected for cardiac catheterization
included those with recent angina or prior PCI; however,
elderly with other high-risk features such as current or
prior heart failure were less likely to receive invasive
care. In order to provide net beneﬁt, invasive care must
be applied with judgment considering comorbidity and
special circumstances in the elderly. However, the marked
variation in the use of invasive care across international
practice suggests a lack of consensus regarding the best
approach to these decisions in elderly patients.
Limitations
Patients selected for clinical trial may be different in many
ways from patients seen in community practice. In the case
of our analysis, it is important to note that the entry criteria
for the SYMPHONY trials excluded patients with a serum
creatinine .1.5 mg/dL. Because the diminished renal func-
tion may reduce the likelihood of a patient undergoing
cardiac catheterization due to concerns of nephrotoxicity
of contrast administration and as diminished renal function
occurs with aging, our results may underestimate disparities
in the use of cardiac catheterization between older and
younger patients. We cannot determine the causality from
our observations. In addition, the use of invasive care may
also be determined by unmeasured comorbidities, frailty,
or patient preferences. We are unable to account for
these confounding variables as these are not currently
assessed in clinical trial databases. In addition, due to
limited resources, some regions may have more than a
30-day wait for catheterization following an index event;
thus, we may underestimate the intended use of cardiac
catheterization in those regions.
Conclusions
While management for ACS differs across international prac-
tice, the directionality of the association between the
patient age and the treatment is shared. Although hypoth-
esis generating, the role of patient age in determining
health care appears most evident in environments with
either low or high use of invasive resources. Best practice
must be regionally deﬁned, but rational care of the elderly
should include an awareness of the importance of invasive
management in selected patients in reducing events
following ACS.
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